A Study of Vitamin D in Subjects With Alopecia Areata

This study has been completed.
Sponsor:
Information provided by:
Avera McKennan Hospital & University Health Center
ClinicalTrials.gov Identifier:
NCT01328678
First received: January 6, 2011
Last updated: July 6, 2011
Last verified: July 2011
  Purpose

The objective of this study is to assess the parathyroid-vitamin D-calcium axis in subjects with alopecia areata. The hypothesis behind this study is that hypovitaminosis D might contribute to the pathogenesis of alopecia areata.


Condition
Alopecia Areata

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pilot Study of Vitamin D in Subjects With Alopecia Areata

Resource links provided by NLM:


Further study details as provided by Avera McKennan Hospital & University Health Center:

Primary Outcome Measures:
  • Vitamin D levels will be reported in subjects and correlated with the calcium and parathyroid levels. [ Time Frame: Initial clinic visit (day 1) ] [ Designated as safety issue: No ]
    This study consists of a single clinic visit. After subject has completed the informed consent process and meets eligibility criteria, a blood sample will be collected. Lab results from this one-time lab draw will be evaluated.


Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 10
Study Start Date: August 2009
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Alopecia Areata
Individuals with Alopecia Areata (AA)

Detailed Description:

Alopecia Areata (AA) is a T-Cell mediated, non-scarring, polygenic, autoimmune disease of the hair follicle. It has been reported to be associated with other autoimmune diseases, especially autoimmune thyroid disease and vitiligo. It is more common in females. Recently, vitamin D deficiency has been claimed to contribute to the pathogenesis of multiple autoimmune disease. There is a strong inverse correlation between the level of 25-hydroxyvitamin D levels and the autoimmune disease in adolescents.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Men and women in and around the Sioux Falls area

Criteria

Inclusion Criteria:

  • Men and women who are at least 18 years old
  • Subjects with newly diagnosed with alopecia areata

Exclusion Criteria:

  • Subjects who take supplemental Vitamin D, by itself or as a part of a multivitamin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01328678

Locations
United States, South Dakota
Avera Research Institute
Sioux Falls, South Dakota, United States, 57105
Sponsors and Collaborators
Avera McKennan Hospital & University Health Center
Investigators
Principal Investigator: Wael Eid, MD Avera McKennan Hospital & University Health Center
  More Information

No publications provided

Responsible Party: Wael Eid, MD, Avera McKennan Hospital & University Health Center
ClinicalTrials.gov Identifier: NCT01328678     History of Changes
Other Study ID Numbers: ARI-1270-Alopecia
Study First Received: January 6, 2011
Last Updated: July 6, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Avera McKennan Hospital & University Health Center:
Alopecia Areata
Vitamin D
Parathyroid
Calcium

Additional relevant MeSH terms:
Alopecia
Alopecia Areata
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Vitamin D
Ergocalciferols
Vitamins
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on July 23, 2014